Greg Cima
Articles Authored by Greg Cima
Hologic Revenues Rise 5 Percent on Strength of Molecular Diagnostics Business
The firm reported a 13 percent jump in its non-COVID molecular diagnostics revenues year over year while its breast health and GYN Surgical business revenues rose 6 percent.
China Instrument Sales Drag on Revvity Life Science Segment as Company Q3 Revenues Rise 2 Percent
Premium
Similar to other firms, the firm said that it has been negatively impacted as customers in China wait for government stimulus funding to arrive.
Endometriosis is associated with debilitating pain and increased risk of cancer and autoimmune diseases, yet diagnosis remains out of reach for many patients.
At the ADLM annual meeting, firms said they see game-changing opportunities for platforms that provide the right combination of clinical utility and convenience.
The Baltimore-based firm is developing multiplex molecular tests for sexually transmitted disease identification and drug susceptibility characterization.
The five-year grant will support the development of a palm-sized instrument and test strips that could provide results within the first weeks following infections.
The team's modification of HotSHOT extraction methods is meant to deliver simple, inexpensive testing to resource-limited areas of sub-Saharan Africa.
The Paris-based startup plans to use €1.5 million in pre-seed funding to support R&D on a test kit and deliver preclinical data by early 2025.
Lynx Dx Sees Possible Reimbursement on Horizon for PCR-Based Prostate Cancer Evaluation Test
Premium
The Michigan-based firm's 18-gene RT-qPCR assay is for distinguishing clinically significant prostate cancer from indolent or slow-growing cancers using urine samples.
Myriad Genetics Revenues Rise 12 Percent in Q1
The firm reported rising revenues across its prenatal, pharmacogenomics, and hereditary cancer testing businesses, although its tumor profiling business dipped year over year.